MCIM
CYCN icon

Meadow Creek Investment Management’s Cyclerion Therapeutics CYCN Stock Holding History

Meadow Creek Investment Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$8K Hold
32
– – ﹤0.01% 1355
2019
Q2 		$7K Buy
+32
New +$9.06K ﹤0.01% 1346

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Meadow Creek Investment Management's CYCN Position: Q3 2019 in Review

Meadow Creek Investment Management held its Cyclerion Therapeutics (CYCN) position steady in Q3 2019 at 32 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1355.

Meadow Creek Investment Management first reported a position in CYCN in Q2 2019 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold CYCN as of Q3 2019.

  • Meadow Creek Investment Management held 32 shares of Cyclerion Therapeutics worth $8K as of Q3 2019.
  • Meadow Creek Investment Management left its Cyclerion Therapeutics share count unchanged in Q3 2019.
  • Cyclerion Therapeutics made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1355 holding.
  • Meadow Creek Investment Management first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.